Found: 36
Select item for more details and to access through your institution.
Metabotropic glutamate receptors as novel targets for anxiety and stress disorders.
- Published in:
- Nature Reviews Drug Discovery, 2005, v. 4, n. 2, p. 131, doi. 10.1038/nrd1630
- By:
- Publication type:
- Article
The AHEAD 3‐45 Study: Design of a prevention trial for Alzheimer's disease.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2023, v. 19, n. 4, p. 1227, doi. 10.1002/alz.12748
- By:
- Publication type:
- Article
Absolute Bioavailability of a Single, Fixed Subcutaneous Dose of Lecanemab in Healthy Subjects.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2022, v. 18, n. 10, p. 1, doi. 10.1002/alz.069438
- By:
- Publication type:
- Article
Subcutaneous Dose Selection of Lecanemab for Treatment of Subjects with Early Alzheimer's Disease (EAD).
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2022, v. 18, n. 10, p. 1, doi. 10.1002/alz.069429
- By:
- Publication type:
- Article
Modeled Impact of APOE4 Genotype on ARIA‐E Incidence in Patients Treated With Lecanemab.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2022, v. 18, n. 10, p. 1, doi. 10.1002/alz.069402
- By:
- Publication type:
- Article
Diversity in Phase 2 and Phase 3 Placebo‐Controlled, Double‐Blind, Lecanemab and Elenbecestat Early Alzheimer's Disease Studies.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2022, v. 18, n. 10, p. 1, doi. 10.1002/alz.069198
- By:
- Publication type:
- Article
Neuropathological autopsy findings in an individual with Alzheimer's disease who received long‐term treatment with lecanemab (BAN2401).
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2022, v. 18, n. 10, p. 1, doi. 10.1002/alz.069220
- By:
- Publication type:
- Article
Lecanemab (BAN2401) Infusion Reactions and Immunogenicity: Results from Randomized Phase 2 Study and an Open‐Label Extension (OLE).
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2022, v. 18, n. 10, p. 1, doi. 10.1002/alz.066289
- By:
- Publication type:
- Article
Derivation and evaluation of signatures using plasma β‐amyloid and pTau‐181 for brain amyloid‐β detection.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2022, v. 18, n. 5, p. 1, doi. 10.1002/alz.067811
- By:
- Publication type:
- Article
Preliminary assessment of the clinical effects of lecanemab following 18 months of treatment in the open label extension of the phase 2 proof of concept study, BAN2401‐G000‐201, in subjects with early Alzheimer's disease.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2021, v. 17, p. 1, doi. 10.1002/alz.057780
- By:
- Publication type:
- Article
Plasma Aβ 42:40 ratio tracks with changes in brain amyloid PET SUVr in the core and open label extension of the phase 2 proof of concept study ban2401‐g000‐201 following treatment with lecanemab in subjects with early Alzheimer's disease.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2021, v. 17, p. 1, doi. 10.1002/alz.057760
- By:
- Publication type:
- Article
Baseline characteristics for CLARITY AD: A phase 3 placebo‐controlled, double‐blind, parallel‐group, 18‐month study evaluating lecanemab (ban2401) in early Alzheimer's disease.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2021, v. 17, p. 1, doi. 10.1002/alz.054331
- By:
- Publication type:
- Article
AHEAD 3‐45 study: Preliminary screening and baseline characteristics from a placebo‐controlled, double‐blind study evaluating lecanemab in participants with preclinical Alzheimer's disease and elevated (A45 trial) and intermediate (A3 trial) amyloid
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2021, v. 17, p. 1, doi. 10.1002/alz.053143
- By:
- Publication type:
- Article
A preliminary assessment of longitudinal amyloid status in the ongoing open‐label extension phase in subjects with early Alzheimer's disease: Human/Human trials: Anti‐amyloid.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2020, v. 16, n. 11, p. 1, doi. 10.1002/alz.046209
- By:
- Publication type:
- Article
A preliminary account of ARIA‐E in the ongoing open‐label extension phase of BAN2401‐G000‐201 in subjects with early Alzheimer's disease: Human/Human trials: Anti‐amyloid.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2020, v. 16, n. 11, p. 1, doi. 10.1002/alz.046059
- By:
- Publication type:
- Article
AHEAD 3‐45 study design: A global study to evaluate the efficacy and safety of treatment with BAN2401 for 216 weeks in preclinical Alzheimer's disease with intermediate amyloid (A3 trial) and elevated amyloid (A45 trial): Clinical trial design and implementation
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2020, v. 16, n. 11, p. 1, doi. 10.1002/alz.044511
- By:
- Publication type:
- Article
P4‐657: POPULATION PHARMACOKINETIC/PHARMACODYNAMIC ANALYSES OF BAN2401 IN PATIENTS WITH EARLY ALZHEIMER'S DISEASE: CORRELATION OF BAN2401 EXPOSURE, PET STANDARD UPTAKE VALUE RATIO, AND COGNITIVE OUTCOMES.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2019, v. 15, p. P1582, doi. 10.1016/j.jalz.2019.09.023
- By:
- Publication type:
- Article
DT‐01‐01: BAN2401 IN EARLY ALZHEIMER'S DISEASE: NEURODEGENERATION BIOMARKER ANALYSIS FROM A RANDOMIZED PHASE 2 STUDY.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2019, v. 15, p. P1484, doi. 10.1016/j.jalz.2019.08.004
- By:
- Publication type:
- Article
DT‐01‐07: TREATMENT OF EARLY AD SUBJECTS WITH BAN2401, AN ANTI‐Aβ PROTOFIBRIL MONOCLONAL ANTIBODY, SIGNIFICANTLY CLEARS AMYLOID PLAQUE AND REDUCES CLINICAL DECLINE.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2018, v. 14, p. P1668, doi. 10.1016/j.jalz.2018.07.009
- By:
- Publication type:
- Article
P4‐291: BASELINE FLORBETAPIR AMYLOID PET STANDARD UPTAKE VALUE RATIO (SUVR) CAN PREDICT CLINICAL PROGRESSION IN PRODROMAL AD.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2018, v. 14, p. P1560, doi. 10.1016/j.jalz.2018.07.113
- By:
- Publication type:
- Article
P1‐361: ASSESSING FUNCTION IN EARLY AD: ANALYSIS OF ALZHEIMER'S DISEASE NEUROIMAGING INITIATIVE (ADNI) 3 DATA FOR THE FINANCIAL CAPACITY INSTRUMENT SHORT FORM (FCI‐SF).
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2018, v. 14, p. P432, doi. 10.1016/j.jalz.2018.06.369
- By:
- Publication type:
- Article
THE FINANCIAL CAPACITY INSTRUMENT–SHORT FORM IS A NOVEL, PERFORMANCE-BASED MEASURE THAT MAY HELP DIFFERENTIATE MILD COGNITIVE IMPAIRMENT AND MILD DEMENTIA DUE TO ALZHEIMER’S DISEASE POPULATIONS IN CLINICAL TRIALS.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2017, v. 13, p. P264, doi. 10.1016/j.jalz.2017.06.137
- By:
- Publication type:
- Article
PHARMACOLOGICAL CHARACTERIZATION OF BAN2401-MEDIATED Aβ PROTOFIBRIL CLEARANCE BY MICROGLIA.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2017, v. 13, p. P625, doi. 10.1016/j.jalz.2017.06.704
- By:
- Publication type:
- Article
Consideration for “early Alzheimer's disease (AD)” trials with a single prodromal AD and mild AD dementia population: ADNI data analysis and initial observations from the BAN2401-G000-201 trial.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2014, v. 10, p. P778, doi. 10.1016/j.jalz.2014.05.1499
- By:
- Publication type:
- Article
Utility of Survival Motor Neuron ELISA for Spinal Muscular Atrophy Clinical and Preclinical Analyses.
- Published in:
- PLoS ONE, 2011, v. 6, n. 8, p. 1, doi. 10.1371/journal.pone.0024269
- By:
- Publication type:
- Article
A Role for Noradrenergic Transmission in the Actions of Phencyclidine and the Antipsychotic and Antistress Effects of mGlu2/3 Receptor Agonists.
- Published in:
- Annals of the New York Academy of Sciences, 2003, v. 1003, n. 1, p. 309, doi. 10.1196/annals.1300.019
- By:
- Publication type:
- Article
Lecanemab for Patients With Early Alzheimer Disease: Bayesian Analysis of a Phase 2b Dose-Finding Randomized Clinical Trial.
- Published in:
- JAMA Network Open, 2023, v. 6, n. 4, p. e237230, doi. 10.1001/jamanetworkopen.2023.7230
- By:
- Publication type:
- Article
ARIA in patients treated with lecanemab (BAN2401) in a phase 2 study in early Alzheimer's disease.
- Published in:
- Alzheimer's & Dementia: Translational Research & Clinical Interventions, 2023, v. 9, n. 1, p. 1, doi. 10.1002/trc2.12377
- By:
- Publication type:
- Article
Lecanemab in patients with early Alzheimer's disease: detailed results on biomarker, cognitive, and clinical effects from the randomized and open-label extension of the phase 2 proof-of-concept study.
- Published in:
- Alzheimer's Research & Therapy, 2022, p. 1, doi. 10.1186/s13195-022-01124-2
- By:
- Publication type:
- Article
Consistency of efficacy results across various clinical measures and statistical methods in the lecanemab phase 2 trial of early Alzheimer's disease.
- Published in:
- Alzheimer's Research & Therapy, 2022, v. 14, n. 1, p. 1, doi. 10.1186/s13195-022-01129-x
- By:
- Publication type:
- Article
Correction: A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer's disease with lecanemab, an anti-Aβ protofibril antibody.
- Published in:
- 2022
- By:
- Publication type:
- Correction Notice
Correction: A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer's disease with lecanemab, an anti-Aβ protofibril antibody.
- Published in:
- 2022
- By:
- Publication type:
- Correction Notice
Correction to: A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer's disease with lecanemab, an anti-Aβ protofibril antibody.
- Published in:
- 2022
- By:
- Publication type:
- Correction Notice
A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer's disease with lecanemab, an anti-Aβ protofibril antibody.
- Published in:
- Alzheimer's Research & Therapy, 2021, v. 13, n. 1, p. 1, doi. 10.1186/s13195-021-00813-8
- By:
- Publication type:
- Article
The mGlu2/3 receptor agonist, LY354740, blocks immobilization-induced increases in noradrenaline and dopamine release in the rat medial prefrontal cortex.
- Published in:
- Journal of Neurochemistry, 2004, v. 88, n. 1, p. 194, doi. 10.1046/j.1471-4159.2003.02125.x
- By:
- Publication type:
- Article
Repeated Cocaine Alters Glutamate Receptor Subunit Levels in the NucleusAccumbens and Ventral Tegmental Area of Rats that Develop BehavioralSensitization.
- Published in:
- Journal of Neurochemistry, 1999, v. 72, n. 6, p. 2397, doi. 10.1046/j.1471-4159.1999.0722397.x
- By:
- Publication type:
- Article